22 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, Mar 9, 2022
Slide 1: MLPCARE 2021 Presentation
MLPCARE 2021 PRESENTATION M A R C H 9 th, 2 0 2 2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava
Slide 3: Muharrem Usta, Chairman & CEO
MUHARREM USTA CHAIRMAN & CEO MLPCARE MEDICALPARK | Lit/nosprtaL
Slide 4: At a Glance: MLP Care 2021 Financial Highlights
At a Glance: MLP Care 2021 Financial Highlights Continued robust uptick in domestic patient revenues and foreign medical tourism revenues quarter-on-quarter (w/o fx impact) Adj. EBITDA Revenue EBITDA improved mainly due to TL 5,796 m TL 1,477 m strong operational performance 44% Growth 54% Gro
Slide 5: # of People with Top-up Insurance Passed PMI
# of People with Top-up Insurance Passed PMI # of People with Insurance in Turkey (in thousand) 2,540 2,595 5,135 2,305 1,607 3,912 Growth (2020 – 2021) 10.2% 61.5% 31.3% PMI Top-up PMI+Top-up # of People with Top-up Insurance in Turkey (in thousand) 12.2021; 2,595 Average LTM Addition to 12.2020; 1
Slide 6: Significant Growth Potential of FMT Revenue
Significant Growth Potential of FMT Revenue Medical Tourism Revenue (USD m) TOP 10 FMT Revenue % by Department in 2021 12.2% 65.5% 32.7% 37.4% 77 80 11% (36.7%) 10% 10% 68 7% 6% 5% 52 4% 3% 3% 3% 49 37 Hematology Hematology Urology Diseases Orthopedics General Surgery Oncology Cardiology Brain and N
Slide 7: Burcu Öztürk, CFO
CFO MLPCARE MEDICALPARK | Lit/nosprtaL
Slide 8: Strong Revenue Growth
Strong Revenue Growth Revenue (TLm) 44.4% 5,796 4,015 46.2% 1,756 1,201 Q4 2020 Q4 2021 2020 2021 Denotes growth of Revenue vs. the same period of the last year 8
Slide 9: Double Digit Growth in Multiple Revenue Segments
Double Digit Growth in Multiple Revenue Segments 2021 (33%) 109% Revenue from SSI was up by 18% in Q4 2021 3% (SSI Insurance allows for a wide addressable market, which is c.98% of the total population) 12% 24% 24% Self pay was up by 29% in Q4 2021 Revenue from PMI, Top-up & Contracted Institu
Slide 10: Strong Domestic and FMT Revenue Growth Continued
Strong Domestic and FMT Revenue Growth Continued Domestic Patient Medical Tourism Ancillary Business Revenue Revenue 43.9% 109.2% (32.7%) 42.8% 4,905 121.4% (22.9%) 179 712 1,448 252 57 Q4 2021 2021 Q4 2021 2021 Q4 2021 2021 Domestic Revenue q-o-q Growth Accelerated Growth of Foreign Decrease in Lab
Slide 11: Continued Improvement in Average Prices
Continued Improvement in Average Prices Outpatient Revenues (TLm) Inpatient Revenues (TLm) 53.3% 37.9% 34.0% 22.4% 19.3% 15.5% 454 464 258 320 2,047 2,857 1,335 2,073 2020 Volume & Mix Price 2021 2020 Volume & Mix Price 2021 Average Revenue Per Visit (ARPV) Average Revenue Per Protocol (ARPP) 500 50
Slide 12: EBITDA Growth on the Back of Strong Revenue Growth
EBITDA Growth on the Back of Strong Revenue Growth EBITDA1 (TLm) EBITDA2 (TLm) (w/o fx impact) 47.4% 54.1% 1,546 1,477 68.9% 1,049 958 68.9% 478 448 283 265 Q4 2020 1 Q4 2021 1 2020 1 2021 1 Q4 2020 2 Q4 2021 2 2020 2 2021 2 1 Adj. EBITDA: EBITDA TFRS adjustments that have no cash impact on relevant
Slide 13: Prudent Cost Management
Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin Adj. EBITDA Margin 26.1% 26.7% Material costs as a % of revenue declined in 2021 due 0.9% 0.9% to decrease in the share of laboratory business which has
Slide 14: Strong Net Profit Improvement
Strong Net Profit Improvement Net Profit (TLm) Net Profit (TLm) Allocated to Equity Holders of the Parent 347.3% 188.8% 355 290 200.8% 96.6% 140 125 123 71 65 42 Q4 2020 Q4 2021 2020 2021 Q4 2020 Q4 2021 2020 2021 Denotes growth of Net Profit and Net Profit Allocated to Equity Holders of the Parent
Slide 15: Net Debt Decreased
Net Debt Decreased FX BASED NET DEBT 1 (in EUR m) GROSS DEBT PERCENTAGE 2020 2021 EUR30m EUR32m EUR22m equivalent of equivalent of equivalent of Cash Balance 680mTL Cash Balance 375mTL FX Cash FX Cash FX Cash Balance Balance Balance 15% 25% 75% 85% 65 51 Net Debt 2,117mTL Net Debt 2,069mTL (13) Nomi
Slide 16: Improved Free Cash Flow and Operating Cash Flow
Improved Free Cash Flow and Operating Cash Flow Maintenance Capex (TLm) Total Capex (TLm) OCF/ EBITDA FCF/ EBITDA 75.0% 106.9% 69.9% 4.0% 8.5% 85.7% 2.3% 1,653 1,160 229 4.1% 493 733 899 92 166 2020 2021 2020 2021 2020 2021 2020 2021 % of Revenue % of Revenue % of EBITDA % of EBITDA 16
Slide 17: Q&A
Q&A MLPCARE MEDICALPARK | Lit/nosprtaL
Slide 18: Closing Remarks
Closing Remarks MUHARREM USTA CHAIRMAN & CEO
Slide 19: Thank You!
Thank You! MLP Care Investor Relations Deniz Can Yücel +90 212 227 5555 (Ext: 1148) deniz.yucel@mlpcare.com http://investor.mlpcare.com/en/
Slide 20: Historical Balance Sheet
Historical Balance Sheet Audited Audited TLm December 31, 2021 December 31, 2020 Cash and cash equivalents 680 375 Trade receivables 1,318 1,155 Inventory 285 113 Short term other assets 458 542 Current assets 2,741 2,185 Tangible and intangible fixed assets 1,716 1,441 Right of use assets 539 257 D
Slide 21: Historical P&L Statements
Historical P&L Statements Audited Audited Unaudited Unaudited TLm 2021 2020 Change (%) Q4 2021 Q4 2020 Change (%) Revenues 5,796 4,015 44.4% 1,756 1,201 46.2% Cost of service (-) (4,217) (3,058) 37.9% (1,248) (909) 37.3% Gross profit 1,579 956 65.1% 508 292 73.9% General administration expenses (-)
Slide 22: Reconciliation from Reported EBITDA to Adjusted EBITDA
Reconciliation from Reported EBITDA to Adjusted EBITDA TLm 2021 2020 Q4 2021 Q4 2020 Net profit / (loss) 355 123 140 71 Tax (income) from operations 17 63 (103) 25 Depreciation and amortization of tangible and intangible fixed assets 336 252 98 64 Total interest expenses/(income) and fair value diff